



Dr. med. Eva Markert

Pathologie · Dept. IV

Kontakt

Dr. med. Eva Markert
Switzerland

T +41 71 494 2125
eva.markert@kssg.ch

Bereiche

Pathologie

Publikationen (7)

Lyatoshinsky P, Pratsinis M, Markert E, Schmid H, Muellhaupt G. Spindle cell/pleomorphic lipoma of the seminal vesicle: First description of a rare benign mesenchymal tumor. *Urol Case Rep* 2023; 47:102337.

Haberecker M, Bühler M, Mendieta A, Guggenberger R, Arnold F, Markert E, Rechsteiner M, Zoche M, Britschgi C, Pauli C. Molecular and immunophenotypic characterization of SMARCB1 (INI1) - deficient intrathoracic Neoplasms. *Mod Pathol* 2022; 35:1860-1869.

Hasan Ali O, Hundsberger T, Diem S, Müller S, Pop O, Markert E, Müller J, Moulin A, Ring S, Ackermann C, Berner F, Flatz L. Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. *Cancer Immunol Immunother* 2020; 70:563-568.

Fehr M, Cathomas G, Graber A, Markert E, Gaus E, Boggian K. Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature. *Med Mycol Case Rep* 2019; 27:14-16.

Amary F, Baumhoer D, O'Donnell P, Pillay N, Lindsay D, Tirabosco R, Cool P, Gerrand C, Ye H, Berisha F, Markert E, Flanagan A. FOS Expression in Osteoid Osteoma and Osteoblastoma: A Valuable Ancillary Diagnostic Tool. *Am J Surg Pathol* 2019; 43:1661-1667.

Hasan Ali O, Diem S, Aschwanden J, Markert E, Tasman A, Müller J, Flatz L. GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography. *JAAD Case Rep* 2016; 2:415-417.

Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French L, Speiser D, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. *Oncoimmunology* 2016; 5:e1231292.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch